Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Long-Term Deferred Tax (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Long-Term Deferred Tax for 12 consecutive years, with $69.1 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax fell 18.84% to $69.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $69.1 million through Dec 2025, down 18.84% year-over-year, with the annual reading at $69.1 million for FY2025, 18.84% down from the prior year.
  • Long-Term Deferred Tax hit $69.1 million in Q4 2025 for Ani Pharmaceuticals, down from $71.4 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $92.0 million in Q2 2025 to a low of $52.0 million in Q1 2021.
  • Historically, Long-Term Deferred Tax has averaged $76.8 million across 5 years, with a median of $79.1 million in 2022.
  • Biggest five-year swings in Long-Term Deferred Tax: soared 41.4% in 2022 and later dropped 19.82% in 2024.
  • Year by year, Long-Term Deferred Tax stood at $67.9 million in 2021, then increased by 19.76% to $81.4 million in 2022, then increased by 11.49% to $90.7 million in 2023, then fell by 6.18% to $85.1 million in 2024, then decreased by 18.84% to $69.1 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for ANIP at $69.1 million in Q4 2025, $71.4 million in Q3 2025, and $92.0 million in Q2 2025.